Idexx (IDXX) Q2 Revenue Jumps 11%
Idexx Laboratories (NASDAQ:IDXX), a leading provider of veterinary diagnostics and software, released its second-quarter earnings on August 4, 2025. The company’s update for the quarter highlighted much stronger than anticipated financial results, led by rapid adoption of new diagnostic products and robust international momentum. Revenue (GAAP) came in at $1,109 million, well above the analyst expectation of $1,066.78 million (GAAP). Diluted earnings per share (EPS) (GAAP) reached $3.63, surpassing the consensus GAAP estimate of $3.30. The company also reported notable progress in its core segments, particularly in its Companion Animal Group (CAG) business line. Overall, the results reflect an acceleration in business activity, though some areas such as rapid assays and free cash flow bear watching as the year continues.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Idexx Laboratories specializes in developing, manufacturing, and distributing diagnostic products and software for animal health, water testing, and livestock safety. Its offerings range from in-clinic diagnostic platforms and reference laboratory services, to integrated software for veterinary practices.
Source Fool.com
